Close Menu

Circulogene

The firm's new RT-PCR assay identifies 20 gene fusion between NTRK1/2/3 and other genes, allowing clinicians to potentially detect rare forms of different cancers.

The deal covers Circulogene's technology for enriching tumor DNA from small volumes of blood for next-generation sequencing-based analysis.

The company's assay relies on proprietary methods of DNA isolation that enable analysis of cell-free DNA from finger-stick volume blood samples.

 

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.